Abdera Therapeutics Inc. is a specialized oncology enterprise advancing next-generation focused radiation treatments, a forefront area in pharmaceutical development. The company is founded on an exclusive adaptable technology platform optimized for administering radioisotopes to selectively eradicate cancer cells while preserving healthy cells. Adhera Therapeutics is a biopharmaceutical company in the clinical phase with a focus on recognizing advanced drug candidates suitable for expedited developmental pathways. Operating as a specialty pharmaceutical company, Adhera Therapeutics conducts research and progresses treatments for inflammatory diseases, hypertension, and cancer. Adhera Therapeutics serves clients in the United States. Aer Therapeutics is a clinical-stage biopharmaceutical organization dedicated to developing an innovative inhaled method for addressing lung diseases characterized by excessive mucus and mucus plugs, targeting conditions such as COPD, cystic fibrosis, and asthma. Their technology stems from collaborative efforts between Dr. John Fahy’s airway biology lab at the University of California San Francisco (UCSF), Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin, and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin.